Table of Contents
ISRN Oncology
Volume 2011, Article ID 523915, 7 pages
http://dx.doi.org/10.5402/2011/523915
Research Article

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution

1Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
2Department of Surgery, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
3Department of Pathology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
4Oncology Department, College of Medicine, King Saud University, 11411 Riyadh, Saudi Arabia

Received 29 May 2011; Accepted 11 July 2011

Academic Editors: C. N. Qian and L. Saragoni

Copyright © 2011 Ninna Aggerholm-Pedersen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Nilsson, P. Bümming, J. M. Meis-Kindblom et al., “Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden,” Cancer, vol. 103, no. 4, pp. 821–829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Langer, B. Gunawan, P. Schüler, W. Huber, L. Füzesi, and H. Becker, “Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours,” British Journal of Surgery, vol. 90, no. 3, pp. 332–339, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Singer, B. P. Rubin, M. L. Lux et al., “Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 3898–3905, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. DeMatteo, J. J. Lewis, D. Leung, S. S. Mudan, J. M. Woodruff, and M. F. Brennan, “Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival,” Annals of Surgery, vol. 231, no. 1, pp. 51–58, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Hirota, K. Isozaki, Y. Moriyama et al., “Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors,” Science, vol. 279, no. 5350, pp. 577–580, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. C. D. Blanke, C. Rankin, G. D. Demetri et al., “Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 626–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Le Cesne, J. Y. Blay, B. N. Bui et al., “Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST),” European Journal of Cancer, vol. 46, no. 8, pp. 1344–1351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST), “Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients,” Journal of Clinical Oncology, vol. 28, pp. 1247–1253, 2010. View at Google Scholar
  9. P. G. Casali, L. Jost, S. Sleijfer, J. Verweij, J. Y. Blay, and ESMO Guidelines Working Group, “Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 20, supplement 4, pp. 132–136, 2009. View at Google Scholar
  10. M. Van Glabbeke, J. Verweij, P. G. Casali et al., “Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group Study,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5795–5804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. C. D. Blanke, G. D. Demetri, M. Von Mehren et al., “Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 620–625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Paules, M. Casey, G. Williams et al., “Recommendations for capture, validation and summarisation of data from studies using RECIST,” European Journal of Cancer, vol. 47, pp. 697–701, 2011. View at Google Scholar
  13. S. S. Mudan, K. C. Conlon, J. M. Woodruff, J. J. Lewis, and M. F. Brennan, “Salvage surgery for patients with recurrent gastrointestinal sarcoma. Prognostic factors to guide-patient selection,” Cancer, vol. 88, no. 1, pp. 66–74, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. G. D. Demetri, M. Von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” The New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Zalcberg, J. Verweij, P. G. Casali et al., “Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg,” European Journal of Cancer, vol. 41, no. 12, pp. 1751–1757, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Verweij, A. Van Oosterom, J. Y. Blay et al., “Imatinib mesylate (STI-571 Glivec®, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study,” European Journal of Cancer, vol. 39, no. 14, pp. 2006–2011, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. V. Glabbeke, J. Verweij, P. G. Casali et al., “Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG),” European Journal of Cancer, vol. 42, no. 14, pp. 2277–2285, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. V. L. Goodman, E. P. Rock, R. Dagher et al., “Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma,” Clinical Cancer Research, vol. 13, no. 5, pp. 1367–1373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. D. Demetri, A. T. van Oosterom, C. R. Garrett et al., “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial,” The Lancet, vol. 368, no. 9544, pp. 1329–1338, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. George, J. Y. Blay, P. G. Casali et al., “Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure,” European Journal of Cancer, vol. 45, no. 11, pp. 1959–1968, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. Yoon, M. H. Ryu, B. Y. Ryoo et al., “Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients,” Investigational New Drugs, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. O. Hansen, P. Sørensen, and K. H. Hansen, “The occurrence of hyponatremia in SCLC and the influence on prognosis. A retrospective study of 453 patients treated in a single institution in a 10-year period,” Lung Cancer, vol. 68, no. 1, pp. 111–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. N. Jeppesen, H. K. Jensen, F. Donskov, N. Marcussen, and H. Von Der Maase, “Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma,” British Journal of Cancer, vol. 102, no. 5, pp. 867–872, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. I. Huo, H. C. Lin, C. Y. Hsia et al., “The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey,” Digestive and Liver Disease, vol. 40, no. 11, pp. 882–889, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. S. Kim, S. Y. Yi, H. J. Jun et al., “Clinical outcome of gastric cancer patients with bone marrow metastases,” Oncology, vol. 73, no. 3-4, pp. 192–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Asadollahi, I. M. Hastings, N. J. Beeching, and G. V. Gill, “Laboratory risk factors for hospital mortality in acutely admitted patients,” QJM, vol. 100, no. 8, pp. 501–507, 2007. View at Publisher · View at Google Scholar · View at Scopus